Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

823.82
+24.743.10%
Post-market: 823.940.1200+0.01%19:58 EDT
Volume:682.68K
Turnover:558.92M
Market Cap:84.82B
PE:20.37
High:824.63
Open:808.86
Low:804.32
Close:799.08
52wk High:847.00
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:1.05
T/O Rate:0.69%
Dividend:3.64
Dividend Rate:0.44%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.67
PE(LYR):19.86

Loading ...

Parabilis Medicines - Intends to Use About $150 Mln of IPO Proceeds to Continue Ongoing Clinical Development of Zolucatetide in Desmoid Tumors

THOMSON REUTERS
·
Jun 04

Parabilis Medicines Inc Says Regeneron Pharmaceuticals Agreed to Buy About $75 Mln of Co's Common Stock in Concurrent Private Placement

THOMSON REUTERS
·
Jun 04

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Jun 04

Movement Alert|Regeneron Pharmaceuticals Rises 3.07% in Regular Trading, WHO Ebola Antibody Recommendation and CytomX Partnership Expansion Boost Shares

Market Focus
·
Jun 04

BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway

Reuters
·
Jun 03

CytomX Therapeutics Expands Cancer Therapy Partnership With Regeneron; Shares Rise

MT Newswires Live
·
Jun 03

BUZZ-CytomX rises on expanded Regeneron deal with up to $4 billion in milestones

Reuters
·
Jun 03

CytomX expands Regeneron bispecific cancer therapy collaboration, receives $37 million payment

Reuters
·
Jun 03

CytomX Therapeutics - Regeneron Secures Option for 6 Additional Targets; Total Milestones up to About $4 Bln

THOMSON REUTERS
·
Jun 03

CytomX Therapeutics - Eligible for Tiered Global Net Sales Royalties Under Collaboration

THOMSON REUTERS
·
Jun 03

Regeneron’s CLIO-1 Update: What a Completed Early Lymphoma Trial Means for REGN Investors

TIPRANKS
·
Jun 03

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) and Regeneron (REGN)

TIPRANKS
·
Jun 02

Regeneron Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Jun 02

FACTBOX-What Bundibugyo Ebola vaccines and treatments are under development

Reuters
·
Jun 01

WHO Ebola Trial Puts Regeneron’s Maftivimab Platform In Investor Focus

Simply Wall St.
·
May 31

Regeneron Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
May 30

Regeneron Advances Phase 3 ROXI-CAT-II Trial, Targeting Safer Cancer-Related Clot Treatment

TIPRANKS
·
May 30

FACTBOX-What Bundibugyo Ebola vaccines and treatments are under development

Reuters
·
May 29

Regeneron Treatment for Ebola Recommended for Priority Evaluation by WHO

Dow Jones
·
May 29

Regeneron Ebola antibody recommended by WHO for investigational use

TIPRANKS
·
May 29